Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.

Abstract

BACKGROUND:

The contribution of p53 and HER-2/neu to the management of node-negative breast cancer (NNBC) could be improved by combining their results.

MATERIAL AND METHODS:

We studied paraffin-embedded primary tumors for p53 (BP-53-12-1) (n=57) and HER2/neu (pAB1) (n=63) from NNBC patients. The results were grouped in a negative (p53(-)/neu(-)) versus a positive group (one or both overexpressed). The association between both groups (negative and positive) and clinicopathologic parameters, S-phase fraction and DNA ploidy, and patients' outcome, was analyzed.

RESULTS:

In 28% of the tumors p53 was overexpressed, and HER2/neu in 11%. Sixty-five percent (37 out of 57) were p53(-)/neu(-), and 35% overexpressed one (31.5%) or both (3.5%) oncoproteins. Significant correlations were found between p53(-)/neu(-) tumors and age greater than 50 (p=0.003), S-phase fraction lower than 7 (p=0.03), and positive estrogen receptor contents (p=0.049). Actuarial 5-year disease-free and overall survival for p53(-)/neu(-) tumors were 88% and 97%, respectively, versus 50% and 66%, for tumors overexpressing one or both oncoproteins (p=0.004).

• Authors: J Albanell, J Bellmunt, R Molina, M García, I Caragol, B Bermejo, A Ribas, J Carulla, O S Gallego, T Español, L A Solé Calvo
• Journal: Anticancer research (Anticancer Res) 1996 Mar-Apr Vol. 16 Issue 2 Pg. 1027-32 ISSN: 0250-7005 [Print] Greece
• PMID: 8687094 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Neoplasm Proteins
• Tumor Suppressor Protein p53
• Receptor, ErbB-2

Topics

• Age Factors
• Breast Neoplasms (chemistry, pathology)
• Disease-Free Survival
• Female
• Humans
• Lymphatic Metastasis (pathology)
• Middle Aged
• Neoplasm Proteins (analysis)
• Neoplasm Recurrence, Local
• Prognosis
• Receptor, ErbB-2 (analysis)
• Risk
• Tumor Suppressor Protein p53 (analysis)